Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 4/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CA7 | P43166 | 2/20 | 0.40 |
| ▸ | CA9 | Q16790 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | TACR1 | P25103 | 2/20 | 0.36 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1934828 | 1.00 | HTT (0.41) | HTTTDP1CA1CA2CA7 | |
| SCHEMBL1934826 | 1.00 | HTT (0.41) | HTTTDP1CA1CA2CA7 | |
| SCHEMBL24025165 | 0.92 | CA1 (0.44) | HTTTDP1CA1CA2CA7 | |
| SCHEMBL19725793 | 0.88 | TDP1 (0.40) | HTTTDP1CA1CA2CA7 | |
| SCHEMBL15366759 | 0.85 | HTT (0.46) | HTTCA1CA2CA7CA9 | |
| SCHEMBL15366764 | 0.85 | HTT (0.46) | HTTCA1CA2CA7CA9 | |
| SCHEMBL15939262 | 0.85 | HTT (0.46) | HTTCA1CA2CA7CA9 | |
| SCHEMBL15366761 | 0.85 | HTT (0.46) | HTTCA1CA2CA7CA9 | |
| SCHEMBL19868233 | 0.83 | CA1 (0.42) | HTTTDP1CA1CA2CA7 | |
| SCHEMBL3301617 | 0.83 | HTT (0.37) | HTTTDP1CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9550795-B2 | Hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds | PFIZER INC. (US) | 2017-01-24 | — | — | US | disclosed |
| EP-2751116-B1 | HEXAHYDROPYRANO [3,4-D][1,3]THIAZIN-2-AMINE COMPOUNDS | PFIZER (US) | 2016-10-12 | — | — | EP | disclosed |
| US-9403846-B2 | Carbocyclic- and heterocyclic-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds | PFIZER INC. (US) | 2016-08-02 | — | — | US | disclosed |
| EP-2852597-B1 | HETEROCYCLIC SUBSTITUTED HEXAHYDROPYRANO [3,4-D][1,3]THIAZIN-2-AMINE COMPOUNDS AS INHIBITORS OF APP, BACE1 AND BACE 2. | PFIZER (US) | 2016-06-08 | — | — | EP | disclosed |
| US-9260455-B2 | Alkyl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds | PFIZER INC. (US) | 2016-02-16 | — | — | US | disclosed |
| US-9233981-B1 | Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds | PFIZER INC. (US) | 2016-01-12 | — | — | US | disclosed |
| US-20160002264-A1 | Carbocyclic- And Heterocyclic-Substituted Hexahydropyrano[3,4-d][1,3]Thiazin-2-Amine Compounds | PFIZER INC. (US) | 2016-01-07 | — | — | US | disclosed |
| US-20150376207-A1 | Substituted Phenyl Hexahydropyrano[3,4-d][1,3]Thiazin-2-Amine Compounds | PFIZER INC. (US) | 2015-12-31 | — | — | US | disclosed |
| US-9198917-B2 | Hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds | PFIZER INC. (US) | 2015-12-01 | — | — | US | disclosed |
| EP-2931731-A1 | HEXAHYDROPYRANO [3,4-D][1,3]THIAZIN-2-AMINE COMPOUNDS AS INHIBITORS OF BACE1 | Pfizer Inc. (US) | 2015-10-21 | — | — | EP | disclosed |
| US-8962616-B2 | Heterocyclic substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds | PFIZER INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-8933221-B2 | Hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds | PFIZER INC. (US) | 2015-01-13 | — | — | US | disclosed |
| US-20140323474-A1 | Hexahydropyrano[3,4-d][1,3]Thiazin-2-Amine Compounds | PFIZER (US) | 2014-10-30 | — | — | US | disclosed |
| US-8822456-B2 | Hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds | PFIZER INC. (US) | 2014-09-02 | — | — | US | disclosed |
| WO-2014091352-A1 | HEXAHYDROPYRANO [3,4-D][1,3]THIAZIN-2-AMINE COMPOUNDS AS INHIBITORS OF BACE1 | PFIZER INC. (US) | 2014-06-19 | — | — | WO | disclosed |
| US-20140163015-A1 | HEXAHYDROPYRANO[3,4-d][1,3]THIAZIN-2-AMINE COMPOUNDS | PFIZER INC. (US) | 2014-06-12 | — | — | US | disclosed |
| WO-2014045162-A1 | ALKYL-SUBSTITUTED HEXAHYDROPYRANO[3,4-d] [1,3]THIAZIN-2-ANIME COMPOUNDS | PFIZER INC. (US) | 2014-03-27 | — | — | WO | disclosed |
| WO-2013164730-A1 | HETEROCYCLIC SUBSTITUTED HEXAHYDROPYRANO [3,4-D] [1,3] THIAZIN- 2 -AMINE COMPOUNDS AS INHIBITORS OF APP, BACE1 AND BACE 2. | PFIZER INC. (US) | 2013-11-07 | — | — | WO | disclosed |
| US-20130296308-A1 | Heterocyclic Substituted Hexahydropyrano[3,4-d][1,3]Thiazin-2-Amine Compounds | PFIZER INC. (US) | 2013-11-07 | — | — | US | disclosed |
| US-20130053373-A1 | Hexahydropyrano[3,4-d][1,3]Thiazin-2-Amine Compounds | BRODNEY MICHAEL AARON (US) | 2013-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140163015-A1 | HEXAHYDROPYRANO[3,4-d][1,3]THIAZIN-2-AMINE COMPOUNDS | TBXA2R, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HTR3D | HTT 157/4885TDP1 395/4885CA1 2701/4885 |
| US-20140323474-A1 | Hexahydropyrano[3,4-d][1,3]Thiazin-2-Amine Compounds | TBXA2R, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HTR3D | HTT 157/4885TDP1 395/4885CA1 2701/4885 |
| US-20160002264-A1 | Carbocyclic- And Heterocyclic-Substituted Hexahydropyrano[3,4-d][1,3]Thiazin-2-Amine Compounds | CYP4B1, HTR3C, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | HTT 1504/4885TDP1 1977/4885CA1 1354/4885 |
| US-20130296308-A1 | Heterocyclic Substituted Hexahydropyrano[3,4-d][1,3]Thiazin-2-Amine Compounds | TPMT, DPYD, UGT1A3 | HTT 122/4885TDP1 419/4885CA1 3038/4885 |
| US-20130053373-A1 | Hexahydropyrano[3,4-d][1,3]Thiazin-2-Amine Compounds | DPYD, TPMT, QDPR | HTT 439/4885TDP1 532/4885CA1 3438/4885 |
| US-20150376207-A1 | Substituted Phenyl Hexahydropyrano[3,4-d][1,3]Thiazin-2-Amine Compounds | TH, QDPR, TBXA2R | HTT 163/4885TDP1 274/4885CA1 3147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.